和黃醫藥(00013.HK):沃瑞沙®於中國首次商業銷售 觸發來自阿斯利康2500萬美元里程碑付款
格隆匯7月13日丨和黃醫藥(00013.HK)發佈公吿,沃瑞沙®(通用名:賽沃替尼/savolitinib)於2021年7月12日首次在中國進行商業銷售。沃瑞沙®是一種強效、高選擇性的口服小分子間質上皮轉化因子(“MET”,一種受體酪氨酸激酶)抑制劑。
這距離沃瑞沙®在中國獲批僅不到三星期時間。沃瑞沙®被批准用於治療接受全身性治療後疾病進展或無法接受化療的MET外顯子14跳躍突變的局部晚期或轉移性非小細胞肺癌(“NSCLC”)患者。
根據和黃醫藥與阿斯利康AstraZeneca AB (publ)之間的許可和合作協議的條款,沃瑞沙®的首次商業銷售將觸發一筆2500萬美元的不可貸記、不可退還的里程碑付款。和黃醫藥負責沃瑞沙®在中國的臨牀開發、上市許可、生產和供應,而阿斯利康則負責其商業化。阿斯利康將根據沃瑞沙®在中國的全部銷售額向和黃醫藥支付30%的固定特許權使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.